



Bovine Viral Diarrhea/Mucosal Disease

Guest Editor:

Dr. Kerstin Wernike

Institute of Diagnostic Virology,
Friedrich-Loeffler-Institut, Federal
Research Institute for Animal
Health, 17493 Greifswald-Insel
Riems, Germany

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editor

Dear colleagues,

Bovine viral diarrhoea virus (BVDV), a flavivirus that exists in the two distinct species *Pestivirus A* and *Pestivirus B*, is endemic in cattle populations worldwide and causes major economic losses and has a significant impact on animal welfare. Hence, fetal protection against all circulating BVDV strains is a major benchmark of vaccination strategies, which might be complicated by the high genetic variability of the virus. Another point to bear in mind when developing anti-BVDV vaccines is their DIVA (differentiation of infected from vaccinated animals) capability, which could assist in ongoing eradication programs that have been implemented in several countries. This Special Issue will focus on the advances in the development of novel vaccines and vaccination strategies against BVD/MD. Besides, the use of vaccines highly depends on legal provisions and the epidemiological situation in a given area. Therefore, studies on the epidemiology of the disease are also welcome.

Dr. Kerstin Wernike
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com